Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of BTK Inhibitor Nemtabrutinib in Combination With Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

NCT06572618 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT06572618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06572618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of BTK Inhibitor Nemtabrutinib in Combination With Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
January 22, 2025
Completion date
January 8, 2027
Enrollment
27 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma